Polycythemia Vera Clinical Trials 2024

What are the top hospitals conducting polycythemia vera research?

When it comes to conducting clinical trials for polycythemia vera, several top hospitals are leading the way in advancing our understanding and treatment of this rare blood disorder. One such institution is The University of Texas MD Anderson Cancer Center in Houston. With five active trials focused on polycythemia vera and a total of seven trials conducted to date, MD Anderson has been at the forefront of research for this condition since their first recorded trial in 2017.

Similarly, Washington University School of Medicine in Saint Louis has also made significant contributions to polycythemia vera research. This esteemed medical school currently has five ongoing clinical trials dedicated to studying the disorder and has conducted a total of five trials thus far since their initial study was recorded in 2019.

The University of Colorado Cancer Center located in Aurora is another prominent hospital actively involved in improving outcomes for patients with polycythemia vera. They currently have four active clinical trials focusing on this condition, building upon their legacy that began with their first recorded trial back in 2015.

In the Bronx, Montefiore Medical Center stands as a vital hub for conducting cutting-edge studies related to polycythemia vera. With four ongoing clinical trials dedicated to exploring new treatments and management strategies, Montefiore Medical Center continues its commitment towards advancements against this disease after recording its first trial just three years ago.

Finally, we turn our attention to Icahn School of Medicine at Mount Sinai situated within bustling New york City. This renowned institution showcases an impressive history with eighteen completed polycythemia vera clinical trials alongside four presently underway endeavors tackling various aspects pertaining to this blood disorder that were initiated by them over a decade ago during2007.Their contribution underscores the significance placed on understanding and fighting against polycythemia vera throughout time

These top hospitals across different locations not only provide hope for those affected by polycythemia vera but also symbolize the collective efforts being made by the medical community to conquer rare diseases. Each trial conducted brings us closer to advancements in treatment and improved quality of life for patients with this condition.

Which are the best cities for polycythemia vera clinical trials?

When it comes to polycythemia vera clinical trials, several cities emerge as top contenders. Houston, Texas leads the way with 26 active trials focusing on promising treatments like parsaclisib, KRT-232, and FEDRATINIB. New york City follows closely behind with 21 ongoing studies exploring interventions such as FEDRATINIB, Pelabresib, and ACE-536. Meanwhile, Saint Louis in Missouri boasts 12 active trials investigating treatments like FEDRATINIB and KRT-232. Toronto in Ontario and Los Angeles in California both have 10 active trials each studying various treatment options for polycythemia vera. These cities provide individuals suffering from this condition access to cutting-edge clinical research that holds promise for improved outcomes and better management of their disease.

Which are the top treatments for polycythemia vera being explored in clinical trials?

Promising treatments are currently being explored in clinical trials for polycythemia vera. One such treatment is KRT-232, which has shown potential in four active trials and marks its first listing in 2019. Another contender is parsaclisib, with two ongoing trials since its introduction in 2021. Last but not least, bomedemstat joins the race as a newcomer with one active trial and a debut listing scheduled for 2023. As researchers delve into these innovative approaches to tackle polycythemia vera, new avenues of hope may soon open up for patients affected by this condition.

What are the most recent clinical trials for polycythemia vera?

Promising advancements have emerged in the field of polycythemia vera, offering hope to those affected by this condition. Notably, clinical trials investigating bomedemstat and reparixin have shown encouraging results. Bomedemstat, in particular, has entered Phase 2 trials and demonstrates potential as a treatment option. Similarly, research on reparixin also indicates positive outcomes for polycythemia vera patients. These recent developments reflect the ongoing efforts to improve therapeutic strategies for managing this disease effectively. With these promising studies underway, individuals with polycythemia vera can look forward to enhanced treatment options on the horizon.

What polycythemia vera clinical trials were recently completed?

Recently, several clinical trials have concluded, bringing us closer to advancements in the treatment of polycythemia vera. In July 2021, Incyte Corporation completed a trial examining the potential of itacitinib as a therapeutic option for this condition. John Mascarenhas also sponsored a trial that reached completion in February 2019, investigating the efficacy of AVID200. Furthermore, Imago BioSciences conducted a trial on IMG-7289 which was completed in July 2017. While earlier but worth mentioning is the completion of a trial on Smac Mimetic LCL161 by M.D. Anderson Cancer Center back in December 2014. These valuable research endeavors shed light on potential breakthroughs and offer hope to individuals living with polycythemia vera.